These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 17181029)
1. Grid-enabled high-throughput in silico screening against influenza A neuraminidase. Lee HC; Salzemann J; Jacq N; Chen HY; Ho LY; Merelli I; Milanesi L; Breton V; Lin SC; Wu YT IEEE Trans Nanobioscience; 2006 Dec; 5(4):288-95. PubMed ID: 17181029 [TBL] [Abstract][Full Text] [Related]
2. Drug screening for influenza neuraminidase inhibitors. Liu A; Cao H; Du G Sci China C Life Sci; 2005 Feb; 48(1):1-5. PubMed ID: 15844351 [TBL] [Abstract][Full Text] [Related]
3. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling. Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092 [TBL] [Abstract][Full Text] [Related]
4. QSAR analyses on avian influenza virus neuraminidase inhibitors using CoMFA, CoMSIA, and HQSAR. Zheng M; Yu K; Liu H; Luo X; Chen K; Zhu W; Jiang H J Comput Aided Mol Des; 2006 Sep; 20(9):549-66. PubMed ID: 17103017 [TBL] [Abstract][Full Text] [Related]
5. Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid. Kasam V; Zimmermann M; Maass A; Schwichtenberg H; Wolf A; Jacq N; Breton V; Hofmann-Apitius M J Chem Inf Model; 2007; 47(5):1818-28. PubMed ID: 17727268 [TBL] [Abstract][Full Text] [Related]
6. Target-induced formation of neuraminidase inhibitors from in vitro virtual combinatorial libraries. Hochgürtel M; Kroth H; Piecha D; Hofmann MW; Nicolau C; Krause S; Schaaf O; Sonnenmoser G; Eliseev AV Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3382-7. PubMed ID: 11891312 [TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of 6-oxo-1,4,5,6-tetrahydropyrimidine-5-carboxylate derivatives as neuraminidase inhibitors. Lou J; Yang X; Rao Z; Qi W; Li J; Wang H; Li Y; Li J; Wang Z; Hu X; Liu P; Hong X Eur J Med Chem; 2014 Aug; 83():466-73. PubMed ID: 24992074 [TBL] [Abstract][Full Text] [Related]
8. The 340-cavity in neuraminidase provides new opportunities for influenza drug development: A molecular dynamics simulation study. Han N; Mu Y; Miao H; Yang Y; Wu Q; Li J; Ding J; Xu B; Huang Z Biochem Biophys Res Commun; 2016 Jan; 470(1):130-136. PubMed ID: 26768362 [TBL] [Abstract][Full Text] [Related]
10. Sensitivity of molecular docking to induced fit effects in influenza virus neuraminidase. Birch L; Murray CW; Hartshorn MJ; Tickle IJ; Verdonk ML J Comput Aided Mol Des; 2002 Dec; 16(12):855-69. PubMed ID: 12825619 [TBL] [Abstract][Full Text] [Related]
11. In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase. Liu H; Yao X; Wang C; Han J Mol Pharm; 2010 Jun; 7(3):894-904. PubMed ID: 20420444 [TBL] [Abstract][Full Text] [Related]
12. Novel aromatic inhibitors of influenza virus neuraminidase make selective interactions with conserved residues and water molecules in the active site. Finley JB; Atigadda VR; Duarte F; Zhao JJ; Brouillette WJ; Air GM; Luo M J Mol Biol; 1999 Nov; 293(5):1107-19. PubMed ID: 10547289 [TBL] [Abstract][Full Text] [Related]
13. Grid enabled high throughput virtual screening against four different targets implicated in malaria. Salzemann J; Kasam V; Jacq N; Maass A; Schwichtenberg H; Breton V Stud Health Technol Inform; 2007; 126():47-54. PubMed ID: 17476047 [TBL] [Abstract][Full Text] [Related]
14. Binding mechanism of H5N1 influenza virus neuraminidase with ligands and its implication for drug design. Gong K; Li L; Wang JF; Cheng F; Wei DQ; Chou KC Med Chem; 2009 May; 5(3):242-9. PubMed ID: 19442214 [TBL] [Abstract][Full Text] [Related]
15. [Creation of a generalized model prediction of inhibition of neuraminidase of influenza virus of various strains]. Mikurova AV; Skvortsov VS Biomed Khim; 2018 Jun; 64(3):247-252. PubMed ID: 29964260 [TBL] [Abstract][Full Text] [Related]
16. Neuraminidase activity provides a practical read-out for a high throughput influenza antiviral screening assay. Eichelberger MC; Hassantoufighi A; Wu M; Li M Virol J; 2008 Sep; 5():109. PubMed ID: 18822145 [TBL] [Abstract][Full Text] [Related]
17. Influenza neuraminidase inhibitors: structure-based design of a novel inhibitor series. Stoll V; Stewart KD; Maring CJ; Muchmore S; Giranda V; Gu YG; Wang G; Chen Y; Sun M; Zhao C; Kennedy AL; Madigan DL; Xu Y; Saldivar A; Kati W; Laver G; Sowin T; Sham HL; Greer J; Kempf D Biochemistry; 2003 Jan; 42(3):718-27. PubMed ID: 12534284 [TBL] [Abstract][Full Text] [Related]
18. Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Varghese JN; Smith PW; Sollis SL; Blick TJ; Sahasrabudhe A; McKimm-Breschkin JL; Colman PM Structure; 1998 Jun; 6(6):735-46. PubMed ID: 9655825 [TBL] [Abstract][Full Text] [Related]
19. Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus. Wang SQ; Du QS; Huang RB; Zhang DW; Chou KC Biochem Biophys Res Commun; 2009 Aug; 386(3):432-6. PubMed ID: 19523442 [TBL] [Abstract][Full Text] [Related]
20. [Prediction of selective inhibition of neuraminidase from various influenza virus strains by potential inhibitors]. Mikurova AV; Rybina AV; Skvortsov VS Biomed Khim; 2016 Nov; 62(6):691-703. PubMed ID: 28026814 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]